Trials / Completed
CompletedNCT01934478
Radiotherapy Alternates Human Epidermal Growth Factor 2 (Her2) Expression in Human Breast Cancer
Study on Human Epidermal Growth Factor 2 (Her2) Expression Changes in Human Breast Cancer After Radiotherapy
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 5 (actual)
- Sponsor
- Qingdao Central Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Based on fundamental study （in Vitro and in Vivo, Pro. Jianjian Li）， Her2 expression would be changed from negative to positive by cancer irradiation with liner-accelerator at dose 6GY or up. The propose of this study is to reveal the irradiation result on Her2 expression in human breast cancer.
Conditions
Timeline
- Start date
- 2013-08-01
- Primary completion
- 2022-12-30
- Completion
- 2022-12-30
- First posted
- 2013-09-04
- Last updated
- 2023-03-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01934478. Inclusion in this directory is not an endorsement.